Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment
Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment
复制标题
贝伐珠单抗全身治疗对视网膜色素上皮脱离的影响
DOI：
10.1136/bjo.2006.102467
复制
发表时间：
2006
影响因子：
4.1
通讯作者：
U. Schmidt
中科院分区：
文献类型：
--
作者：
M. Bolz;S. Michels;W. Geitzenauer;F. Prager;U. Schmidt
背景：评价阿瓦斯丁单抗治疗老年性黄斑变性(AMD)继发的色素上皮脱离(PED)的疗效，找出影响PED消退和最佳矫正视力(BCVA)改善的预后因素。研究设计：前瞻性非对照先导性研究。方法：9例(9只眼)患者每隔2周接受3次全身性贝伐单抗治疗，分别于基线、1周、2周、4周、6周和3个月进行光学相干断层扫描(Stratus OCT™，Carl Zeiss©Meditec，都柏林，美国加利福尼亚州)。用Adobe Photoshop CS软件对最大PED高度和最大线性直径(GLD)的变化进行平面测量分析，并与视网膜形态变化和BCVA变化进行相关性分析。结果：系统贝伐单抗治疗耐受性良好。平均最大PED高度在1周内显著下降21%(−96微米(SD48.8)，p<；0.01)。术后3个月两个PED完全消失，平均最大PED高度下降39%(−179µm(SD 178)，p = 0.02)，平均PED GLD下降24%(−714µm(SD 1010)，p = 0.07)。术后第2周(+8.7个字母(SD 5.7)，P<；0.01)和3个月时的12.7个字母(SD 6.4)的平均BCVA均有显著改善(P<；0.01)。结论：在被检查的9名患者中，系统贝伐单抗治疗通过减少病变高度和直径，显示了继发于新生血管性AMD的PED的效果。基线水平的高PED被发现是视力结果的负面预测因素。
Background: To evaluate the effect of systemic bevacizumab (Avastin®) therapy on pigment epithelial detachment (PED) secondary to age-related macular degeneration (AMD) and to identify prognostic factors for PED regression and improvement in best corrected visual acuity (BCVA). Study design: Prospective uncontrolled pilot study. Methods: Nine patients (nine eyes) received three systemic bevacizumab treatments at 2 week intervals and were examined at baseline, weeks 1, 2, 4, 6 and month 3 by using optical coherence tomography (Stratus OCT™, Carl Zeiss© Meditec, Dublin, California, USA). Changes in maximum PED height and greatest linear diameter (GLD) were planimetrically analysed by using Adobe Photoshop CS and correlated with retinal morphological changes and changes in BCVA. Results: Systemic bevacizumab therapy was well tolerated. Mean maximum PED height decreased significantly by 21% as early as 1 week (−96 µm (SD 48.8), p<0.01). At 3 months follow-up, two PEDs resolved completely, mean maximum PED height decreased significantly by 39% (−179 µm (SD 178), p = 0.02) and mean PED GLD by 24% (−714 µm (SD 1010), p = 0.07). Mean BCVA improved significantly by week 2 (+8.7 letters (SD 5.7), p<0.01) and at 3 months with 12.7 letters (SD 6.4) (p<0.01). Conclusion: In the examined nine patients, systemic bevacizumab therapy showed evidence for an effect on PED secondary to neovascular AMD in terms of a decrease in lesion height and diameter. A high PED at baseline was found to be a negative predictive factor for visual outcome.
影响因子：
13.7
作者：
Hee, MR;Baumal, CR;Fujimoto, JG
通讯作者：
Fujimoto, JG
影响因子：
158.5
作者：
Hurwitz, H;Fehrenbacher, L;Kabbinavar, F
通讯作者：
Kabbinavar, F
吲哚菁绿血管造影引导光凝治疗与视网膜色素上皮脱离相关的脉络膜新生血管。
影响因子：
4.2
作者：
Lim,JI;Aaberg,TM;CaponeJr,A;SternbergJr,P
通讯作者：
SternbergJr,P